Salud financiera de hoja de balance de Avricore Health

Salud financiera controles de criterios 6/6

Avricore Health tiene un patrimonio de accionistas total de CA$2.3M y una deuda total de CA$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CA$2.6M y CA$341.2K respectivamente. El BAIT de Avricore Health es de CA$57.6K, por lo que su ratio de cobertura de intereses es de -52.4. Tiene efectivo e inversiones a corto plazo que ascienden a CA$565.6K.

Información clave

Ratio deuda-patrimonio

CA$0

Deuda

Ratio de cobertura de intereses	-52.4x
Efectivo	CA$565.61k
Patrimonio	CA$2.28m
Total pasivo	CA$341.18k
Activos totales	CA$2.62m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CA$950.3K) de 8VP1 superan a sus pasivos a corto plazo (CA$341.2K).

Pasivo a largo plazo: 8VP1 no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: 8VP1 está libre de deudas.

Reducción de la deuda: 8VP1 no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable 8VP1 tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: 8VP1 no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 15.3% al año.

Salud financiera de hoja de balance de Avricore Health

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

New major risk - Market cap size

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 2Q 2022)

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

New 90-day high: €0.36

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera